-
Product Insights
LGB Aus – One North Terrace Development – South Australia
Equip yourself with the essential tools needed to make informed and profitable decisions with our LGB Aus - One North Terrace Development - South Australia report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Sector Analysis
Lebanon Cards and Payments – Opportunities and Risks to 2026
The Lebanon cards and payments market size was $2.8 billion in 2021. The market is projected to achieve a CAGR of more than 19% during the forecast period. The Lebanon cards and payments report provides a detailed analysis of market trends in the Lebanon cards and payments industry. It provides values and volumes for several key performance indicators in the industry, including mobile wallets, cards, cash, credit transfers, direct debits, and cheques during the review period. The report also analyzes...
-
Product Insights
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine/Threonine Protein Kinase Pim 3 pipeline market research report provides comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players...
-
Product Insights
Serine/Threonine Protein Kinase Pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
The serine/threonine protein kinase pim 2 (Pim 2h or Proto Oncogene Pim 2 or PIM2 or EC 2.7.11.1) targeted pipeline therapeutics report provides comprehensive information on the serine/threonine protein kinase pim 2 targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides...
-
Product Insights
Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) Development by Therapy Areas and Indications, Stages, MoA, RoA, Molecule Type and Key Players, 2022 Update
Serine/Threonine Protein Kinase Pim 1 pipeline market research report provides comprehensive information on the Serine/Threonine Protein Kinase Pim 1 (Oncogene PIM1 or PIM1 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved...
-
Product Insights
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2021 Update
Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) pipeline Target constitutes close to 10 molecules. Out of which approximately 9 molecules are developed by companies and remaining by the universities/institutes. The latest report SerineThreonine Protein Kinase Pim 3 - Drugs in Development, 2021, outlays comprehensive information on the Serine/Threonine Protein Kinase Pim 3 (Pim 3 Oncogene or PIM3 or EC 2.7.11.1) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA),...